Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 347

1.

Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.

Wohlbold TJ, Nachbagauer R, Xu H, Tan GS, Hirsh A, Brokstad KA, Cox RJ, Palese P, Krammer F.

MBio. 2015 Mar 10;6(2):e02556. doi: 10.1128/mBio.02556-14.

2.

Advances in the development of influenza virus vaccines.

Krammer F, Palese P.

Nat Rev Drug Discov. 2015 Mar;14(3):167-82. doi: 10.1038/nrd4529. Review.

PMID:
25722244
3.

Preexisting human antibodies neutralize recently emerged H7N9 influenza strains.

Dunand CJ, Leon PE, Kaur K, Tan GS, Zheng NY, Andrews S, Huang M, Qu X, Huang Y, Salgado-Ferrer M, Ho IY, Taylor W, Hai R, Wrammert J, Ahmed R, García-Sastre A, Palese P, Krammer F, Wilson PC.

J Clin Invest. 2015 Mar 2;125(3):1255-68. doi: 10.1172/JCI74374. Epub 2015 Feb 17.

PMID:
25689254
4.

Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.

He W, Mullarkey CE, Duty JA, Moran TM, Palese P, Miller MS.

J Virol. 2015 Apr;89(7):3610-8. doi: 10.1128/JVI.03099-14. Epub 2015 Jan 14.

PMID:
25589655
5.

Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.

Goff PH, Hayashi T, Martínez-Gil L, Corr M, Crain B, Yao S, Cottam HB, Chan M, Ramos I, Eggink D, Heshmati M, Krammer F, Messer K, Pu M, Fernandez-Sesma A, Palese P, Carson DA.

J Virol. 2015 Mar;89(6):3221-35. doi: 10.1128/JVI.03337-14. Epub 2015 Jan 7.

PMID:
25568203
6.

The nucleoprotein of newly emerged H7N9 influenza A virus harbors a unique motif conferring resistance to antiviral human MxA.

Riegger D, Hai R, Dornfeld D, Mänz B, Leyva-Grado V, Sánchez-Aparicio MT, Albrecht RA, Palese P, Haller O, Schwemmle M, García-Sastre A, Kochs G, Schmolke M.

J Virol. 2015 Feb;89(4):2241-52. doi: 10.1128/JVI.02406-14. Epub 2014 Dec 10.

PMID:
25505067
7.

Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin.

Tan GS, Lee PS, Hoffman RM, Mazel-Sanchez B, Krammer F, Leon PE, Ward AB, Wilson IA, Palese P.

J Virol. 2014 Dec;88(23):13580-92. doi: 10.1128/JVI.02289-14. Epub 2014 Sep 10.

PMID:
25210195
8.

Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.

Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F.

J Virol. 2014 Nov;88(22):13260-8. doi: 10.1128/JVI.02133-14. Epub 2014 Sep 10.

9.

Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.

Ellebedy AH, Krammer F, Li GM, Miller MS, Chiu C, Wrammert J, Chang CY, Davis CW, McCausland M, Elbein R, Edupuganti S, Spearman P, Andrews SF, Wilson PC, García-Sastre A, Mulligan MJ, Mehta AK, Palese P, Ahmed R.

Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13133-8. doi: 10.1073/pnas.1414070111. Epub 2014 Aug 25.

10.

Long-term survival of influenza virus infected club cells drives immunopathology.

Heaton NS, Langlois RA, Sachs D, Lim JK, Palese P, tenOever BR.

J Exp Med. 2014 Aug 25;211(9):1707-14. doi: 10.1084/jem.20140488. Epub 2014 Aug 18.

11.

Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin.

Krammer F, Palese P, Steel J.

Curr Top Microbiol Immunol. 2015;386:301-21. doi: 10.1007/82_2014_408. Review.

PMID:
25007847
12.

Peering into the crystal ball: influenza pandemics and vaccine efficacy.

Miller MS, Palese P.

Cell. 2014 Apr 10;157(2):294-9. doi: 10.1016/j.cell.2014.03.023.

PMID:
24725400
13.

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP.

Sci Transl Med. 2014 Mar 5;6(226):226ra32. doi: 10.1126/scitranslmed.3008095.

14.

Divergent H7 immunogens offer protection from H7N9 virus challenge.

Krammer F, Albrecht RA, Tan GS, Margine I, Hai R, Schmolke M, Runstadler J, Andrews SF, Wilson PC, Cox RJ, Treanor JJ, García-Sastre A, Palese P.

J Virol. 2014 Apr;88(8):3976-85. doi: 10.1128/JVI.03095-13. Epub 2014 Jan 22.

15.

Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.

DiLillo DJ, Tan GS, Palese P, Ravetch JV.

Nat Med. 2014 Feb;20(2):143-51. doi: 10.1038/nm.3443. Epub 2014 Jan 12.

16.

Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.

Krammer F, Hai R, Yondola M, Tan GS, Leyva-Grado VH, Ryder AB, Miller MS, Rose JK, Palese P, García-Sastre A, Albrecht RA.

J Virol. 2014 Mar;88(6):3432-42. doi: 10.1128/JVI.03004-13. Epub 2014 Jan 8.

17.

Universal influenza virus vaccines: need for clinical trials.

Krammer F, Palese P.

Nat Immunol. 2014 Jan;15(1):3-5. doi: 10.1038/ni.2761. No abstract available.

PMID:
24352315
18.

Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.

Hai R, Schmolke M, Leyva-Grado VH, Thangavel RR, Margine I, Jaffe EL, Krammer F, Solórzano A, García-Sastre A, Palese P, Bouvier NM.

Nat Commun. 2013;4:2854. doi: 10.1038/ncomms3854.

19.

H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge.

Krammer F, Margine I, Hai R, Flood A, Hirsh A, Tsvetnitsky V, Chen D, Palese P.

J Virol. 2014 Feb;88(4):2340-3. doi: 10.1128/JVI.03183-13. Epub 2013 Dec 4.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk